Regulus Therapeutics News

Express News | Regulus Therapeutics Announces Promotion of Rekha Garg, M.d., M.s., to Chief Medical Officer

ReutersMay 16 08:00 ET

Buy Rating Affirmed for Regulus Therapeutics Amid Positive Clinical Advances for RGLS8429

TipRanksMay 10 06:46 ET

Express News | Regulus Therapeutics Inc: Ended Q1 With Cash, Cash Equivalents, and Investments of $107.7 Mln; Cash Runway Into H1 2026

ReutersMay 9 17:12 ET

Regulus Therapeutics | 10-Q: Quarterly report

Futu NewsMay 9 16:32 ET · Announcements

Express News | Regulus Therapeutics Q1 Pretax Profit USD -8.469 Million

ReutersMay 9 16:05 ET

Express News | Regulus Therapeutics Q1 Basic EPS USD -0.29

ReutersMay 9 16:05 ET

Express News | Regulus Therapeutics Q1 Income From Operations USD -8.826 Million

ReutersMay 9 16:05 ET

Express News | Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates

ReutersMay 9 16:05 ET

Express News | Regulus Therapeutics Q1 Operating Expenses USD 8.826 Million

ReutersMay 9 16:05 ET

12 Health Care Stocks Moving In Monday's After-Market Session

GainersAgape ATP (NASDAQ:ATPC) shares rose 23.0% to $0.32 during Monday's after-market session. The market value of their outstanding shares is at $24.9 million. FibroGen (NASDAQ:FGEN) shares increase

BenzingaMay 6 16:31 ET

Optimistic Buy Rating for Regulus Therapeutics' RGLS8429 Amid Promising ADPKD Treatment Progress

TipRanksMay 6 11:45 ET

Express News | Regulus Therapeutics Advances to Cohort 4 of Phase 1B Multiple-Ascending Dose (Mad) Clinical Trial of Rgls8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (Adpkd)

ReutersMay 6 08:00 ET

Earnings Week Ahead: Disney, Palantir, Shopify, Uber, Plug Power and More

Seeking AlphaMay 5 08:00 ET

Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series

SAN DIEGO, April 30, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (t

PR NewswireApr 30 08:00 ET

Regulus Files to Sell 62.5M Shares of Common Stock for Holders

Seeking AlphaApr 9 17:06 ET

Buy Rating Reaffirmed for Regulus Therapeutics Amid Promising Drug Development Milestones

TipRanksMar 25 06:26 ET

Regulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancements

Yahoo FinanceMar 23 05:33 ET

Regulus Therapeutics: Oversubscribed $100M Private Placement to Extend Cash Runway Into 1H of 2026 >RGLS

Regulus Therapeutics: Oversubscribed $100M Private Placement to Extend Cash Runway Into 1H of 2026 >RGLS

Dow JonesMar 21 16:13 ET

Express News | Regulus Therapeutics Q4 EPS $(0.40) Misses $(0.39) Estimate

Moomoo 24/7Mar 21 16:08 ET

Regulus Therapeutics 4Q Loss $8.06M >RGLS

Regulus Therapeutics 4Q Loss $8.06M >RGLS

Dow JonesMar 21 16:05 ET